Abstract

The results of the latest research more and more bind development of neoplasms with the chronic inflammation. Inflammatory process creates microenvironment promoting development of neoplasms; as a result, malignant process start to develop in places, where chronic inflammation proceeds or regeneration of tissues takes place. Inflammatory cells not only create suitable microenvironment for development of neoplasms, but also excrete number of cytokines and growth factors promoting survival of a neoplasmatic cell and avoiding its apoptosis, promoting neoangiogenesis and metastases formation. Moreover, cytokines and other pro-inflammatory factors modulate expression of genes important in cancerogenesis, they also activate NFκB-dependent signaling pathways, which favor neoplasmatic cells to avoid apoptosis. On the other hand, oxidative stress accompanying chronic inflammation may promote mutagenesis, enabling that way the neoplasm development. The same cells and metabolic pathways are engaged in inflammatory and neoplasmatic processes, and development of cancer may be a consequence of loss of control over tissue regeneration during resolution of chronic inflammation. The role of most important cells and metabolic pathways in inflammatory process, which may lead to colon cancer, was discussed in this paper.

References

• 1. Algra A.M., Rothwell P.M.: Effects of regular aspirin on long-termcancer incidence and metastasis: a systematic comparison of evidencefrom observational studies versus randomised trials. LancetOncol., 2012; 13: 518-527
  Google Scholar
• 2. Beachy P.A., Karhadkar S.S., Berman D.M.: Tissue repair and stemcell renewal in carcinogenesis. Nature, 2004; 432: 324-331
  Google Scholar
• 3. Beaugerie L., Svrcek M., Seksik P., Bouvier A.M., Simon T., AllezM., Brixi H., Gornet J.M., Altwegg R., Beau P., Duclos B., BourreilleA., Faivre J., Peyrin-Biroulet L., Fléjou J.F., Carrat F.; CESAME StudyGroup: Risk of colorectal high-grade dysplasia and cancer in a prospectiveobservational cohort of patients with inflammatory boweldisease. Gastroenterology, 2013; 145: 166-175.e8
  Google Scholar
• 4. Benamouzig R., Deyra J., Martin A., Girard B., Jullian E., PiednoirB., Couturier D., Coste T., Little J., Chaussade S.: Daily soluble aspirinand prevention of colorectal adenoma recurrence: one-year resultsof the APACC trial. Gastroenterology, 2003; 125: 328-336
  Google Scholar
• 5. Biswas S.K., Sica A., Lewis C.E.: Plasticity of macrophage functionduring tumor progression: regulation by distinct molecular mechanisms.J. Immunol., 2008; 180: 2011-2017
  Google Scholar
• 6. Burn J., Bishop D.T., Chapman P.D., Elliott F., Bertario L., DunlopM.G., Eccles D., Ellis A., Evans D.G., Fodde R., Maher E.R.,Möslein G., Vasen H.F., Coaker J., Phillips R.K., Bülow S., MathersJ.C.; International CAPP consortium: A randomized placebo–controlled prevention trial of aspirin and/or resistant starchin young people with familial adenomatous polyposis. CancerPrev. Res., 2011; 4: 655-665
  Google Scholar
• 7. Burn J., Gerdes A.M., Macrae F., Mecklin J.P., Moeslein G., OlschwangS., Eccles D., Evans D.G., Maher E.R., Bertario L., BisgaardM.L., Dunlop M.G., Ho J.W., Hodgson S.V., Lindblom A. i wsp.; CAPP2Investigators: Long-term effect of aspirin on cancer risk in carriersof hereditary colorectal cancer: an analysis from the CAPP2 randomisedcontrolled trial. Lancet, 2011; 378: 2081-2087
  Google Scholar
• 8. Egeblad M., Rasch M.G., Weaver V.M.: Dynamic interplay betweenthe collagen scaffold and tumor evolution. Curr. Opin. Cell Biol.,2010; 22: 697-706
  Google Scholar
• 9. Ginis I., Faller D.V.: Protection from apoptosis in human neutrophilsis determined by the surface of adhesion. Am. J. Physiol.,1997; 272: C295-C309
  Google Scholar
• 10. Hadler-Olsen E., Winberg J.O., Uhlin-Hansen L.: Matrix metalloproteinasesin cancer: their value as diagnostic and prognosticmarkers and therapeutic targets. Tumour Biol., 2013; 34: 2041-2051
  Google Scholar
• 11. Hoang B.H., Kubo T., Healey J.H., Yang R., Nathan S.S., Kolb E.A.,Mazza B., Meyers P.A., Gorlick R.: Dickkopf 3 inhibits invasion andmotility of Saos-2 osteosarcoma cells by modulating the Wnt-β-catenin pathway. Cancer Res., 2004; 64: 2734-2739
  Google Scholar
• 12. Kettritz R., Xu Y.X., Kerren T., Quass P., Klein J.B., Luft F.C., HallerH.: Extracellular matrix regulates apoptosis in human neutrophils.Kidney Int., 1999; 55: 562-571
  Google Scholar
• 13. Kwak J.M., Lee H.J., Kim S.H., Kim H.K., Mok Y.J., Park Y.T., ChoiJ.S., Moon H.Y.: Expression of protein S100A4 is a predictor of recurrencein colorectal cancer. World J. Gastroenterol., 2010; 16: 3897-3904
  Google Scholar
• 14. Lakatos G., Hritz I., Varga M.Z., Juhász M., Miheller P., CiernyG., Tulassay Z., Herszényi L.: The impact of matrix metalloproteinasesand their tissue inhibitors in inflammatory bowel diseases. Dig.Dis., 2012; 30: 289-295
  Google Scholar
• 15. Lakatos P.L., Lakatos L.: Risk for colorectal cancer in ulcerativecolitis: changes, causes and management strategies. World J. Gastroenterol.,2008; 14: 3937-3947
  Google Scholar
• 16. Logan R.F., Grainge M.J., Shepherd V.C., Armitage N.C., MuirK.R.; ukCAP Trial Group: Aspirin and folic acid for the prevention ofrecurrent colorectal adenomas. Gastroenterology, 2008; 134: 29-38
  Google Scholar
• 17. Mariani F., Sena P., Roncucci L.: Inflammatory pathways in theearly steps of colorectal cancer development. World J. Gastroenterol.,2014; 20: 9716-9731
  Google Scholar
• 18. McCowan C., Munro A.J., Donnan P.T., Steele R.J.: Use of aspirininpost-diagnosis in a cohort of patients with colorectal cancer and itsassociation with all-cause and colorectal cancer specific mortality.Eur. J. Cancer, 2013; 49: 1049-1057
  Google Scholar
• 19. McKenzie B.S., Kastelein R.A., Cua D.J.: Understanding the IL-23-IL-17 immune pathway. Trends Immunol., 2006; 27: 17-23
  Google Scholar
• 20. Murray P.J., Wynn T.A.: Protective and pathogenic functions ofmacrophage subsets. Nat. Rev. Immunol., 2011; 11: 723-737
  Google Scholar
• 21. Mutoh M., Watanabe K., Kitamura T., Shoji Y., Takahashi M.,Kawamori T., Tani K., Kobayashi M., Maruyama T., Kobayashi K.,Ohuchida S., Sugimoto Y., Narumiya S., Sugimura T., WakabayashiK.: Involvement of prostaglandin E receptor subtypeEP(4) in coloncarcinogenesis. Cancer Res., 2002; 62: 28-32
  Google Scholar
• 22. Roncucci L., Mora E., Mariani F., Bursi S., Pezzi A., Rossi G., PedroniM., Luppi D., Santoro L., Monni S., Manenti A., Bertani A., MerighiA., Benatti P., Di Gregorio C., de Leon P.M.: Myeloperoxidase-positivecell infiltration in colorectal carcinogenesis as indicator of colorectalcancer risk. Cancer Epidemiol. Biomarkers Prev., 2008; 17: 2291-2297
  Google Scholar
• 23. Sandler R.S., Halabi S., Baron J.A., Budinger S., Paskett E., KeresztesR., Petrelli N., Pipas J.M., Karp D.D., Loprinzi C.L., SteinbachG., Schilsky R.: A randomized trial of aspirin to prevent colorectaladenomas in patients with previous colorectal cancer. N. Engl. J.Med., 2003; 348: 883-890
  Google Scholar
• 24. Satoh S., Daigo Y., Furukawa Y., Kato T., Miwa N., Nishiwaki T.,Kawasoe T., Ishiguro H., Fujita M., Tokino T., Sasaki Y., Imaoka S., MurataM., Shimano T., Yamaoka Y., Nakamura Y.: AXIN1 mutations inhepatocellular carcinomas, and growth suppression in cancer cellsby virus-mediated transfer of AXIN1. Nat. Genet., 2000; 24: 245-250
  Google Scholar
• 25. Sena P., Roncucci L., Marzona L., Mariani F., Maffei S., ManentiA., De Pol A.: Altered expression of apoptosis biomarkers in humancolorectal microadenomas. Cancer Epidemiol. Biomarkers Prev.,2010; 19: 351-357
  Google Scholar
• 26. Solinas G., Germano G., Mantovani A., Allavena P.: Tumor-associatedmacrophages (TAM) as major players of the cancer-relatedinflammation. J. Leukoc. Biol., 2009; 86: 1065-1073
  Google Scholar
• 27. Talieri M., Papadopoulou S., Scorilas A., Xynopoulos D., ArnogianakiN., Plataniotis G., Yotis J., Agnanti N.: Cathepsin B and cathepsinD expression in the progression of colorectal adenoma tocarcinoma. Cancer Lett., 2004; 205: 97-106
  Google Scholar
• 28. Tsujino T., Seshimo I., Yamamoto H., Ngan C.Y., Ezumi K., TakemasaI., Ikeda M., Sekimoto M., Matsuura N., Monden M.: Stromalmyofibroblasts predict disease recurrence for colorectal cancer. Clin.Cancer Res., 2007; 13: 2082-2090
  Google Scholar
• 29. Verkaar F., Zaman G.J.: New avenues to target Wnt/β-cateninsignaling. Drug Discov. Today, 2011; 16: 35-41
  Google Scholar
• 30. Wang D., DuBois R.N.: The role of anti-inflammatory drugs incolorectal cancer. Annu. Rev. Med., 2013; 64: 131-144
  Google Scholar
• 31. Wojtyniak B., Goryński P., Moskalewicz B.: Sytuacja zdrowotnaludności Polski i jej uwarunkowania. Narodowy Instytut ZdrowiaPublicznego – Państwowy Zakład Higieny, ISBN 83-89379-63-5,Warszawa 2012
  Google Scholar
• 32. Xouri G., Christian S.: Origin and function of tumor stroma fibroblasts.Semin. Cell Dev. Biol., 2010; 21: 40-46
  Google Scholar

Full text